Gabapentin
Product Images NDC 58517-060

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 58517-060). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by New Horizon Rx Group, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Chemical Structure (01e45240 Figure 01)

Chemical Structure (01e45240 Figure 01)
FDA Label Image

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (01e45240 Figure 02)

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (01e45240 Figure 02)
FDA Label Image

Figure 2.  Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (01e45240 Figure 03)

Figure 2.  Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (01e45240 Figure 03)
This is a study report about the mean pain score during a week dose titration period followed by a fixed dose period. The data compares the placebo effect with two different doses of Gabapentin (1800 mg/day and 2400 mg/day) over a period of 7 weeks. The study concluded that both doses of Gabapentin significantly reduced the mean pain score compared to the placebo (p<001). No further information about the study or the source is available from the given text.*
FDA Label Image

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (01e45240 Figure 04)

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (01e45240 Figure 04)
FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study (01e45240 Figure 05)

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study (01e45240 Figure 05)
FDA Label Image

01e45240-figure-06 (01e45240 Figure 06)

01e45240-figure-06 (01e45240 Figure 06)
This appears to be a prescription medication label for Gabapentin capsules in the US. The medication is provided in the form of capsules, and the total cost is listed as €101. The label also includes various codes and identifiers, such as "NDC 58517-060-30" and "2900£ V1".*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.